APA (7th ed.) Citation

Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., . . . Ribas, A. (2023). Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. The New England journal of medicine, 388(9), 813-823. https://doi.org/10.1056/NEJMoa2211437

Chicago Style (17th ed.) Citation

Patel, Sapna P., et al. "Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma." The New England Journal of Medicine 388, no. 9 (2023): 813-823. https://doi.org/10.1056/NEJMoa2211437.

MLA (9th ed.) Citation

Patel, Sapna P., et al. "Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma." The New England Journal of Medicine, vol. 388, no. 9, 2023, pp. 813-823, https://doi.org/10.1056/NEJMoa2211437.